Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer.

Yan-Song Lin Shu-Kui Qin Hui Yang Feng Shi Aimin Yang Xingmin Han Bin Liu Zhiyong Li Qinghai Ji Lijun Tang Zhiyong Deng Yong Ding Wei Fu Xianhe Xie Linfa Li Xiaohui He Zhongwei Lv Qingjie Ma Zan Shen Zhuming Guo Zhendong Chen Yali Cui Jian Tan Zairong Gao Shanghua Jing Keyi Lu Xianyang Luo Yuan Zhang Yong Fang Zhendong Li Yizhuang Cheng Shangtong Lei Sha Luan Guang Chen Guihua Wang Liqing Wu Lingling Liu

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Donafenib was well-tolerated, and demonstrated clinical benefit in terms of improved PFS, ORR and DCRin patients with RAIR-DTC. The results suggest that donafenib could be a new treatment option for RAIR-DTC patients.

Keyphrases

phase iii
double blind
placebo controlled
open label
clinical trial
phase ii
end stage renal disease
study protocol
newly diagnosed
chronic kidney disease
multiple sclerosis
ejection fraction
prognostic factors
magnetic resonance
randomized controlled trial
patient reported outcomes
replacement therapy